{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:39:17Z","timestamp":1783708757036,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>A MASCC\/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise resource for clinicians that concentrates practical information needed for the management of oral complications of cancer patients. This CPS focuses on the use of imaging and clinical laboratory tests for the diagnosis, staging, monitoring, treatment decision, and prediction of medication-related osteonecrosis of the jaw (MRONJ) in cancer patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This CPS was developed based on a critical evaluation of the literature followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group (OCSG) of MASCC\/ISOO. The information is presented in the form of succinct bullets and tables to generate a short manual about the best standard of care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Radiographs, cone beam computerized tomography (CT), conventional CT, magnetic resonance imaging (MRI), and nuclear imaging are often utilized in patients with MRONJ. The CPS describes the considerations for selecting each imaging modality. Laboratory workup in patients with MRONJ is often derived by comorbidities, with immune status and bleeding tendency being the key considerations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Imaging and lab tests have an important role in the diagnosis and management of MRONJ. The imaging modality and specific laboratory tests should be tailored to the patient\u2019s needs.\n<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09809-8","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T06:37:16Z","timestamp":1757745436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MASCC\/ISOO Clinical Practice Statement: imaging and clinical laboratory tests in the diagnosis and management of medication-related osteonecrosis of the jaw"],"prefix":"10.1007","volume":"33","author":[{"given":"Noam","family":"Yarom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragda","family":"Abdalla-Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Migliorati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Livshits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Amir","family":"Rais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonse","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo R.","family":"Fregnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kivanc","family":"Bektas-Kayhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Elad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"issue":"2","key":"9809_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","volume":"27","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, Elad S, Campisi G, Tsoukalas N, Bektas -Kayhan K, Tan W, Body JJ, Migliorati C, Lalla RV, MASCC Bone Study Group (2019) Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer 27(2):383\u2013394. https:\/\/doi.org\/10.1007\/s00520-018-4501-x","journal-title":"Support Care Cancer"},{"issue":"13","key":"9809_CR2","doi-asserted-by":"publisher","first-page":"1017391","DOI":"10.3389\/fphar.2022.1017391","volume":"19","author":"J Peng","year":"2022","unstructured":"Peng J, Wang H, Liu Z, Xu ZL, Wang MX, Chen QM, Wu ML, Ren XL, Liang QH, Liu FP, Ban B (2022) Real-world study of antiresorptive-related osteonecrosis of jaw based on the US Food and Drug Administration adverse event reporting system database. Front Pharmacol 19(13):1017391. https:\/\/doi.org\/10.3389\/fphar.2022.1017391","journal-title":"Front Pharmacol"},{"issue":"5","key":"9809_CR3","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg 80(5):920\u2013943. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"issue":"7","key":"9809_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.21.02647","volume":"40","author":"A Eisen","year":"2022","unstructured":"Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, Dillmon MS, D\u2019Oronzo S, Fletcher GG, Frank ES, Hallmeyer S, Makhoul I, Moy B, Thawer A, Wu JY, Van Poznak CH (2022) Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. J Clin Oncol 40(7):787\u2013800. https:\/\/doi.org\/10.1200\/JCO.21.02647","journal-title":"J Clin Oncol"},{"issue":"8","key":"9809_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00520-024-08687-w","volume":"32","author":"N Yarom","year":"2024","unstructured":"Yarom N, Van Poznak CH, Epstein JB, Ottaviani G, Matsuda Y, Migliorati C, Elad S (2024) MASCC\/ISOO clinical practice statement: adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw. Support Care Cancer 32(8):547. https:\/\/doi.org\/10.1007\/s00520-024-08687-w","journal-title":"Support Care Cancer"},{"issue":"25","key":"9809_CR6","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP (2019) Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol 37(25):2270\u20132290. https:\/\/doi.org\/10.1200\/JCO.19.01186","journal-title":"J Clin Oncol"},{"issue":"6","key":"9809_CR7","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1111\/odi.14887","volume":"30","author":"A Bedogni","year":"2024","unstructured":"Bedogni A, Mauceri R, Fusco V, Bertoldo F, Bettini G, Di Fede O, Lo Casto A, Marchetti C, Panzarella V, Saia G, Vescovi P, Campisi G (2024) Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ). Oral Dis 30(6):3679\u20133709. https:\/\/doi.org\/10.1111\/odi.14887","journal-title":"Oral Dis"},{"issue":"11","key":"9809_CR8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","volume":"123","author":"S Fedele","year":"2010","unstructured":"Fedele S, Porter SR, D\u2019Aiuto F, Aljohani S, Vescovi P, Manfredi M, Arduino PG, Broccoletti R, Musciotto A, Di Fede O, Lazarovici TS, Campisi G, Yarom N (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123(11):1060\u20131064. https:\/\/doi.org\/10.1016\/j.amjmed.2010.04.033","journal-title":"Am J Med"},{"issue":"5 Suppl","key":"9809_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.joms.2008.12.002","volume":"67","author":"K Arce","year":"2009","unstructured":"Arce K, Assael LA, Weissman JL, Markiewicz MR (2009) Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg 67(5 Suppl):75\u201384. https:\/\/doi.org\/10.1016\/j.joms.2008.12.002","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"9809_CR10","doi-asserted-by":"publisher","DOI":"10.1259\/dmfr.20160065","volume":"45","author":"C Klingelh\u00f6ffer","year":"2016","unstructured":"Klingelh\u00f6ffer C, Klingelh\u00f6ffer M, M\u00fcller S, Ettl T, Wahlmann U (2016) Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw? Dentomaxillofac Radiol 45(5):20160065. https:\/\/doi.org\/10.1259\/dmfr.20160065","journal-title":"Dentomaxillofac Radiol"},{"key":"9809_CR11","doi-asserted-by":"publisher","unstructured":"Wongratwanich P, Shimabukuro K, Konishi M, Nagasaki T, Ohtsuka M, Suei Y, Nakamoto T, Verdonschot RG, Kanesaki T, Sutthiprapaporn P, Kakimoto N (2022) Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review. Dentomaxillofac Radiol 50(6):20200417. https:\/\/doi.org\/10.1259\/dmfr.20200417. Epub 2021 Jan 15. Erratum in: Dentomaxillofac Radiol. 2022 May 1;51(4):20200417c. https:\/\/doi.org\/10.1259\/dmfr.20200417.c","DOI":"10.1259\/dmfr.20200417"},{"key":"9809_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2023.110916","volume":"165","author":"Z Yfanti","year":"2023","unstructured":"Yfanti Z, Tetradis S, Nikitakis NG, Alexiou KE, Makris N, Angelopoulos C, Tsiklakis K (2023) Radiologic findings of osteonecrosis, osteoradionecrosis, osteomyelitis and jaw metastatic disease with cone beam CT. Eur J Radiol 165:110916. https:\/\/doi.org\/10.1016\/j.ejrad.2023.110916","journal-title":"Eur J Radiol"},{"issue":"1","key":"9809_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2500\/ajra.2017.31.4395","volume":"31","author":"O Wasserzug","year":"2017","unstructured":"Wasserzug O, Kaffe I, Lazarovici TS, Weissman T, Yahalom R, Fliss DM, Yarom N (2017) Involvement of the maxillary sinus in bisphosphonate-related osteonecrosis of the jaw: radiologic aspects. Am J Rhinol Allergy 31(1):36\u201339. https:\/\/doi.org\/10.2500\/ajra.2017.31.4395","journal-title":"Am J Rhinol Allergy"},{"issue":"3","key":"9809_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00784-009-0293-1","volume":"14","author":"P Stockmann","year":"2010","unstructured":"Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, Nkenke E (2010) Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig 14(3):311\u2013317. https:\/\/doi.org\/10.1007\/s00784-009-0293-1","journal-title":"Clin Oral Investig"},{"issue":"8","key":"9809_CR15","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1158\/1078-0432.CCR-07-1430","volume":"14","author":"N Raje","year":"2008","unstructured":"Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC (2008) Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 14(8):2387\u20132395. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1430","journal-title":"Clin Cancer Res"},{"issue":"4","key":"9809_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/diagnostics14040428","volume":"14","author":"CP Reinert","year":"2024","unstructured":"Reinert CP, Pfannenberg C, G\u00fcckel B, Dittmann H, la Foug\u00e8re C, Nikolaou K, Reinert S, Sch\u00f6nhof R, Hoefert S (2024) Preoperative assessment of medication-related osteonecrosis of the jaw using [18F] fluoride positron emission tomography (PET)\/CT and [18F] fluorodeoxyglucose PET\/MRI in correlation with histomorphometry and micro-CT-a prospective comparative study. Diagnostics 14(4):428. https:\/\/doi.org\/10.3390\/diagnostics14040428","journal-title":"Diagnostics"},{"issue":"7","key":"9809_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/dmfr\/twae034","volume":"53","author":"K Kur","year":"2024","unstructured":"Kur K, Papadopoulou E, Nidam M, Fertouk M, Binyamini O, Friedlander Barenboim S, Lazarovitci TS, Domachevsky L, Yarom N (2024) The diagnostic value of prostate-specific membrane antigen PET-CT in differentiating medication-related osteonecrosis of the jaw and metastasis to the jawbone. Dentomaxillofac Radiol 53(7):497\u2013500. https:\/\/doi.org\/10.1093\/dmfr\/twae034","journal-title":"Dentomaxillofac Radiol"},{"issue":"21","key":"9809_CR18","doi-asserted-by":"publisher","first-page":"6590","DOI":"10.3390\/jcm11216590","volume":"11","author":"C Lauri","year":"2022","unstructured":"Lauri C, Chiurchioni L, Russo VM, Zannini L, Signore A (2022) PSMA expression in solid tumors beyond the prostate gland: ready for theranostic applications? J Clin Med 11(21):6590. https:\/\/doi.org\/10.3390\/jcm11216590","journal-title":"J Clin Med"},{"issue":"2","key":"9809_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/RLU.0000000000001926","volume":"43","author":"T Lengana","year":"2018","unstructured":"Lengana T, Lawal I, Boshomane T, Ololade K, Reyneke F, Kaoma C, Mokgoro N, Vorster M, Sathekge M (2018) Salivary gland activity obscures mandibular metastasis of prostate carcinoma on 68Ga-prostate-specific membrane antigen PET. Clin Nucl Med 43(2):106\u2013109. https:\/\/doi.org\/10.1097\/RLU.0000000000001926","journal-title":"Clin Nucl Med"},{"issue":"6","key":"9809_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00277-007-0263-0","volume":"86","author":"L Catalano","year":"2007","unstructured":"Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B (2007) Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. Ann Hematol 86(6):415\u2013423. https:\/\/doi.org\/10.1007\/s00277-007-0263-0","journal-title":"Ann Hematol"},{"issue":"S","key":"9809_CR21","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00774-019-00994-1","volume":"37","author":"Y Kojima","year":"2019","unstructured":"Kojima Y, Kawaoka Y, Sawada S, Hayashida S, Okuyama K, Yutori H, Kawakita A, Ishida S, Soutome S, Yanamoto S, Umeda M, Iwai H (2019) Clinical significance of periosteal reaction as a predictive factor for treatment outcome of medication-related osteonecrosis of the jaw. J Bone Miner Metab 37(S):913\u2013919. https:\/\/doi.org\/10.1007\/s00774-019-00994-1","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"9809_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11282-017-0293-9","volume":"34","author":"R Kubo","year":"2018","unstructured":"Kubo R, Ariji Y, Taniguchi T, Nozawa M, Katsumata A, Ariji E (2018) Panoramic radiographic features that predict the development of bisphosphonate-related osteonecrosis of the jaw. Oral Radiol 34(2):151\u2013160. https:\/\/doi.org\/10.1007\/s11282-017-0293-9","journal-title":"Oral Radiol"},{"issue":"8","key":"9809_CR23","doi-asserted-by":"publisher","DOI":"10.1259\/dmfr.20230238","volume":"52","author":"C Moreno Rabie","year":"2023","unstructured":"Moreno Rabie C, Cavalcante Fontenele R, Oliveira Santos N, Nogueira Reis F, Van den Wyngaert T, Jacobs R (2023) Three-dimensional clinical assessment for MRONJ risk in oncologic patients following tooth extractions. Dentomaxillofac Radiol 52(8):20230238. https:\/\/doi.org\/10.1259\/dmfr.20230238","journal-title":"Dentomaxillofac Radiol"},{"issue":"4","key":"9809_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5125\/jkaoms.2018.44.4.174","volume":"44","author":"WJ Shin","year":"2018","unstructured":"Shin WJ, Kim CH (2018) Prognostic factors for outcome of surgical treatment in medication-related osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg 44(4):174\u2013181. https:\/\/doi.org\/10.5125\/jkaoms.2018.44.4.174","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"issue":"1","key":"9809_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/jop.13112","volume":"50","author":"A Mamilos","year":"2021","unstructured":"Mamilos A, Sp\u00f6rl S, Spanier G, Ettl T, Brochhausen C, Klingelh\u00f6ffer C (2021) The first quantitative histomorphological analyses of bone vitality and inflammation in surgical specimens of patients with medication-related osteonecrosis of the jaw. J Oral Pathol Med 50(1):76\u201384. https:\/\/doi.org\/10.1111\/jop.13112","journal-title":"J Oral Pathol Med"},{"issue":"3","key":"9809_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.bjoms.2016.01.009","volume":"54","author":"T M\u00fccke","year":"2016","unstructured":"M\u00fccke T, Jung M, Mitchell DA, Wolff KD, Wagenpfeil S, Stockmann P, Kesting MR, Deppe H (2016) Do measurements of inflammatory mediators in blood predict recurrence in patients with bisphosphonate-related osteonecrosis of the jaws? Br J Oral Maxillofac Surg 54(3):286\u2013289. https:\/\/doi.org\/10.1016\/j.bjoms.2016.01.009","journal-title":"Br J Oral Maxillofac Surg"},{"key":"9809_CR27","doi-asserted-by":"publisher","unstructured":"Schubert L, Russmueller G, Lagler H, Tobudic S, Heindel E, Kundi M, Steininger C (2021) Bone turnover markers can predict healing time in medication-related osteonecrosis of the jaw. Support Care Cancer. https:\/\/doi.org\/10.1007\/s00520-021-06361-z","DOI":"10.1007\/s00520-021-06361-z"},{"issue":"9","key":"9809_CR28","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","volume":"68","author":"TS Lazarovici","year":"2010","unstructured":"Lazarovici TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, Yahalom R, Taicher S, Yarom N (2010) Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg 68(9):2241\u20132247. https:\/\/doi.org\/10.1016\/j.joms.2010.05.043","journal-title":"J Oral Maxillofac Surg"},{"issue":"8","key":"9809_CR29","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.joms.2014.02.036","volume":"72","author":"A Hutcheson","year":"2014","unstructured":"Hutcheson A, Cheng A, Kunchar R, Stein B, Sambrook P, Goss A (2014) A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study. J Oral Maxillofac Surg 72(8):1456\u20131462. https:\/\/doi.org\/10.1016\/j.joms.2014.02.036","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09809-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09809-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09809-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T03:39:24Z","timestamp":1760672364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09809-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["9809"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09809-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N Yarom, R Abdalla-Aslan, C Migliorati, E Livshits, RA Mohammed, W Park, ER Fregnani, K Bektas-Kayhan, and S Elad reported no relevant financial or non-financial interests to disclose. C. Migliorati is an adjudicator for Amgen Inc. JB. Epstein is a consultant for Rakuten, Sanotize Inc., Janssen, Neilsen Inc. J.B. Epstein is also the Associate Editor-in-Chief for Supportive Care in Cancer.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The MASCC\/ISOO OCSG Statements have been developed to facilitate expert-opinion-based management of oral complications of cancer and cancer therapy where high-quality evidence is lacking. Clinicians should use their judgment when making treatment decisions for individual patients. Statement authors and the MASCC\/ISOO do not guarantee or take responsibility for the clinical outcomes in individual patients.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"852"}}